10.1016/j.tibs.2021.10.004 84 KmiecikS
Disease modifying agents capable of controlling obesity with meaningful metabolic improvement have reshaped expectations for both clinicians and patients ( Nausea and vomiting remain among the most frequent and disruptive adverse effects across Glucagon-like peptide (GLP-1)-based therapies ( In this opinion article, we examine the mechanisms underlying nausea and vomiting in semaglutide, CagriSema, survodutide, tirzepatide, retatrutide, and orforglipron and situate them within obesity clinical practice ( We also propose practical strategies to mitigate gastrointestinal intolerance
Surgery performed while you are still actively losing can produce a result that shifts as your body keeps changing
While hair loss becomes increasingly more common with age, hormonal shifts and stress can also trigger excessive shedding and slowed growth
Subcutaneous injection delivers the peptide directly into your tissue with near-100% absorption
Conjugation of acrylamide with glutathione catalysed by glutathione-S-transferases of [PMID: 7271861] Laboratory literature summary: Conjugation of acrylamide with glutathione catalysed by glutathione-S-transferases of rat liver and brain